NCT03994796
Genetic Testing in Guiding Treatment for Patients With Brain Metastases
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 55 versions: 46 with changes below, 4 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Results posted: Oct 30, 2026
- Secondary endpoints revised (10)
- Site details revised at 1 of 435 sites
- Notable Eligibility criteria expanded, about 36 words
- Primary completion date changed from estimate of Oct 2026 to Nov 13, 2025
- Study description revised
- Site details revised at 43 of 435 sites
- Notable Trial status: Suspended to Active, Not Recruiting
- Enrollment target: estimated 186 to confirmed 50
- Minor Study sites revised (435)v52
- Minor Study sites revised (435)v50
Show 41 earlier versionsHide 41 earlier versions
- Minor Study sites revised (435)v48
- Stopped Trial status: Recruiting to Suspended Sponsor's reason: Interim analysis
- Study sites: 437 to 435
- Minor Site details revised at 7 of 437 sitesv45
- Minor Study sites revised (437)v44
- Notable Primary completion date: Oct 2025 to Oct 2026
- Start date: Aug 15, 2019 to Oct 17, 2019
- Study completion date: Jun 2026 to Jun 2028
- Site details revised at 178 of 437 sites
- Notable Primary completion date: Oct 2024 to Oct 2025
- Study sites: 426 to 437
- Study completion date: Jun 2025 to Jun 2026
- Minor Study sites revised (426)v41
- Minor Study sites revised (426)v40
- Minor Study sites: 424 to 426v39
- Minor Study sites revised (424)v38
- Minor Study sites: 417 to 424v37
- Minor Study sites: 416 to 417v36
- Minor Study sites: 405 to 416v35
Notable Eligibility criteria expanded, about 433 wordsv34 Show 4 more changesShow less
- Enrollment target: 150 to 186
- Interventions: Abemaciclib (Drug), Entrectinib (Drug), PI3K Inhibitor paxalisib (Drug) to Abemaciclib (Drug), Adagrasib (Drug), Entrectinib (Drug), PI3K Inhibitor paxalisib (Drug)
- Study description expanded, about 63 words
- Study arms: 3 to 4
- Minor Study sites: 387 to 405v33
- Minor Study sites: 386 to 387v32
- Minor Site details revised at 5 of 386 sitesv31
- Minor Site details revised at 18 of 386 sitesv30
- Minor Study sites: 380 to 386v29
- Minor Site details revised at 50 of 380 sitesv28
- Minor Site details revised at 17 of 380 sitesv27
- Minor Study sites: 379 to 380v26
- Minor Site details revised at 189 of 379 sitesv25
- Minor Site details revised at 14 of 379 sitesv24
- Minor Study sites: 369 to 379v23
- Minor Study sites: 365 to 369v22
- Notable Primary completion date: Jul 2021 to Oct 2024v21
- Minor Study sites: 355 to 365
- Interventions: Abemaciclib (Drug), Entrectinib (Drug), PI3K Inhibitor GDC-0084 (Drug) to Abemaciclib (Drug), Entrectinib (Drug), PI3K Inhibitor paxalisib (Drug)
- Minor Study sites: 354 to 355v19
- Minor Study sites: 351 to 354v18
- Minor Study sites: 349 to 351v17
- Minor Study sites: 347 to 349v16
- Minor Study sites: 348 to 347v15
- Minor Study sites: 342 to 348v13
- Minor Study sites: 330 to 342v12
- Minor Study sites: 309 to 330v11
- Minor Study sites: 306 to 309v10
- Minor Study sites: 304 to 306v9
- Minor Study sites: 297 to 304v8
- Minor Study sites: 283 to 297v7
- Minor Study sites: 254 to 283v6
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
Patients receive abemaciclib PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive PI3K inhibitor paxalisib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive entrectinib PO QD on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients receive adagrasib (MRTX849) PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Drugs: Abemaciclib, PI3K Inhibitor paxalisib, Entrectinib, Adagrasib
Sites
435 sites in 1 country